
Trial Insights from TROPiCS-02 and DESTINY-Breast06 in HR+/HER2– Breast Cancer
The optimal sequencing of antibody-drug conjugates (ADCs) in the treatment of metastatic hormone receptor (HR)–positive, HER2-negative breast cancer is a critical area of investigation. Recent data from the phase 3 TROPiCS-02 (NCT03901339) and DESTINY- …